Intellectual property
Patent portfolio
GeNeuro's patent portfolio protects a broad platform of innovations targeting human endogenous retrovirus (HERV) biology — from foundational antibody compositions to novel therapeutic mechanisms to clinical laboratory tests for detecting HERV proteins in patients. All patents listed below are publicly registered in multiple global jurisdictions.
GeNeuro × US National Institutes of Health
A landmark co-invention between GeNeuro Inc and the US Department of Health and Human Services (NIH), with Hervé Perron and Avindra Nath as co-inventors, produced the first monoclonal antibody specifically targeting the HERV-K envelope protein — the causative driver of motor neuron degeneration in ALS. Developed under a Cooperative Research and Development Agreement (CRADA) with the NIH/NINDS, GeNeuro's antibody GNK-301 was shown to prevent motor neuron degeneration in mouse brains and human brain cells in culture.
Anti-HERV-K envelope antibody and uses thereof
US granted patent covering a novel monoclonal antibody (GN_mAb_Env_K01) targeting a conserved, glycosylation-independent linear epitope on the HERV-K envelope protein. The antibody neutralises HERV-K Env cytotoxicity in human neuronal cultures, restoring cell viability, neurite length, and electrophysiological activity. Co-invented with the NIH/NINDS.
Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
Discloses the discovery that HERV-W Env protein directly blocks oligodendrocyte precursor cell (OPC) differentiation via TLR4, preventing remyelination in MS lesions. Demonstrates that anti-HERV-W Env antibody (GNbAC1/temelimab) reverses this remyelination blockade in human OPC cultures and in EAE animal models.
Pharmaceutical composition containing antibodies directed against the HERV-W envelope
Foundational patent covering pharmaceutical compositions comprising antibodies directed against the HERV-W envelope protein, excluding antibodies targeting the hASCT1/hASCT2 receptor binding site. Establishes the core anti-HERV-W Env antibody therapeutic concept.
Therapeutic use of specific ligand in MSRV-associated diseases
Covers the therapeutic use of a specific humanized IgG4 ligand (temelimab/GNbAC1) defined by six CDR sequences for treatment of MSRV-related diseases including MS, psychosis, Type 1 Diabetes, and related neurological and autoimmune conditions. Includes extensive preclinical and clinical validation data.
Antiretroviral drug targeting human endogenous retrovirus
Covers the use of an antibody, fragment, or derivative directed against HERV-W Env protein as an antiretroviral drug targeting viruses belonging to the HERV-W type family. Granted in Australia and active in multiple jurisdictions.
Anti-HERV-W envelope protein antibody for use in the treatment of psychotic diseases
Covers the use of an anti-HERV-W Env antibody for treating patients diagnosed with psychotic disease who are characterised by elevated cytokine levels in body fluid — establishing a precision medicine approach to HERV-W targeted therapy in psychosis.
Method for detecting HERV-W envelope protein in a biological sample
Covers an in vitro diagnostic method for detecting HERV-W envelope protein in a biological sample using a specific antibody, establishing a clinical laboratory test for HERV-W Env expression as a biomarker in MS and related HERV-W associated diseases. PCT application WO2014/184241 with granted national phase entries in the US and Europe.
Patent data sourced from Google Patents public records. Publication numbers, filing dates, and inventor/assignee information reflect publicly available registry data. Patent families may include additional national phase entries not listed here. GeNeuro SA reserves all rights under applicable intellectual property law.